FOLFIRI in advanced platinum-resistant/refractory small-cell lung cancer: a retrospective study

Figures & data

Figure 1. Flow chart. SCLC: small-cell lung cancer; FOLFIRI: 5fluorouracile irinotecan; PFS: progression free-survival; OS: overall survival; ORR: objective response rate.

Table 1. Patients baseline characteristics.

	n = 34
Median age, years (IQR)	63 (45-84)
Sex
Male	23 (67.6%)
Female	11 (32.3%)
ECOG, PS
0	0 (0%)
1	24 (70.6%)
≥2	10 (29.4%)
Recurrence after initial locoregional treatment	6 (17.6%)
Nature of prior chemotherapy regimen
Platinum-etoposide	19 (55.9%)
Platinum-etoposide/platinum-etoposide	10 (29.4%)
Platinum-etoposide/paclitaxel	3 (8.8%)
Platinum-etoposide/platinum-etoposide/platinum-etoposide	1 (2.9%)
Platinum-etoposide/topotecan/adriamycin-cyclophosphamide	1 (2.9%)
Platinum sensitivity at FOLFIRI initiation
Platinum resistant	14 (41.2%)
Platinum refractory	20 (58.8%)
CNS metastases
Yes	17 (50%)
No	17 (50%)

IQR: interquartile range; ECOG: Eastern Cooperative Oncology Group; PS: performance status; CNS: central nervous system.

Figure 2. Waterfall plot of radiological objective response. RECIST, Response Evaluation Criteria for Solid Tumors version 1.1; PD, progressive disease; PR, partial response; SD, stable disease; EORTC, European Organization for Research and Treatment of Cancer.

Figure 3. (A) Kaplan Meier of progression free-survival. (B) Kaplan Meier of overall survival.

Table 2. Analysis of tumor response.

	Evaluable population	Overall population
	n = 28	n = 34
Objective response rate
Overall	5/28 (17.9%)	5/34 (14.7%)
Platinum-resistant	3/10 (30.0%)	3/14 (21.4%)
Platinum-refractory	2/18 (11.1%)	2/20 (10%)
Disease control rate	14/28 (50%)	14/34 (41.2%)
Best overall response
Complete response	0 (0%)	0 (0%)
Partial response	5/28 (17.9%)	5/34 (14.7%)
Stable disease	9/28 (32.1%)	9/34 (26.5%)
Progressive disease	14/28 (50%)	14/34 (41.2%)
Unknown	0/28 (0%)	6/34 (17.6%)
Median (IQR) duration of responses, among patients with objective response	40.1 weeks (34.6–52)

IQR: interquartile range.

Table 3. Safety profile.

	Grade ≥3 (n = 34)
Any event	13 (38.2%)
Diarrhea	2 (5.9%)
Hematotoxicity	5 (14.7%)
Thrombopenia	2 (5.9%)
Neutropenia	3 (8.8%)
Anemia	0
Asthenia	5 (14.7%)
Dose reduction	11 (32.4%)
Causes of dose reduction
Asthenia	3 (27.3%)
Digestive toxicity	2 (18.2%)
Hematotoxicity	5 (45.5%)
Unknown	1 (9.1%)

Grade according to Common Terminology Criteria for Adverse Events (CTCAE) V5.0.

Data availability statement

The data that support the findings of this study are available from the corresponding author, [BA], upon reasonable request.